LON:INS Instem (INS) Share Forecast, Price & News GBX 825.10 +0.10 (+0.01%) (As of 04:00 PM ET) Add Compare Share Share Today's Range 825▼ 825.1050-Day Range 588▼ 83052-Week Range 550▼ 830Volume231,451 shsAverage Volume72,442 shsMarket Capitalization£188.95 millionP/E Ratio5,893.57Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Instem (LON:INS) StockInstem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.Read More INS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INS Stock News HeadlinesSeptember 15, 2023 | marketwatch.comInstem Swung to 1H Pretax Loss Amid Higher CostsSeptember 1, 2023 | thetimes.co.ukInstem board ‘absurd’ to back £203m bidSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 1, 2023 | msn.comALEX BRUMMER: Investors who shunned UKAugust 31, 2023 | finanznachrichten.deSamson Rock Capital LLP - Re-issue: Form 8.3 - Instem PlcAugust 31, 2023 | finance.yahoo.comForm 8.3 - INS LNAugust 31, 2023 | uk.finance.yahoo.comSamson Rock Capital LLP - Form 8.3 - Instem PlcAugust 30, 2023 | msn.comInstem bought by French private equity firm Archimed SAS in £200m dealSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 30, 2023 | usnews.comUK's Instem Soars on $257 Million Take-Private Offer From French PE FirmAugust 30, 2023 | theguardian.comStaffordshire-based Instem bought by private equity group Archimed for £203mAugust 30, 2023 | lse.co.ukAIM WINNERS & LOSERS: Instem soars on GBP200 million takeoverAugust 30, 2023 | lse.co.ukTOP NEWS: Instem accepts GBP200 million takeover offer from ArchimedAugust 30, 2023 | reuters.comUK's Instem soars on $257 mln take-private offer from French PE firmAugust 30, 2023 | finance.yahoo.comUK's Instem shares pop on $257 million take-private deal from French firmAugust 30, 2023 | finance.yahoo.comForm 8.3 - INSTEM PLCAugust 30, 2023 | markets.businessinsider.comInstem Agrees To Be Acquired By ARCHIMED In GBP 203 Mln DealAugust 30, 2023 | marketwatch.comInstem Agrees to GBP203 Mln Takeover by Ichor ManagementAugust 15, 2023 | marketwatch.comInstem Sees 2023 Performance In Line With Its Views After 1H Revenue GrowthJuly 4, 2023 | msn.comBengaluru: NCBS launches Rohini Nilekani Centre for Brain and Mind for research on severe mental illnessesJune 28, 2023 | marketwatch.comInstem's Executive Pay, Auditor Reappointment Get Low Shareholder Support at AGMJune 2, 2023 | finance.yahoo.comInstem plc (LON:INS) Shares Could Be 32% Below Their Intrinsic Value EstimateMay 17, 2023 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And Instem (LON:INS) Passed With EaseMay 15, 2023 | lse.co.ukInstem acquires new platform following annual profit growthMay 15, 2023 | marketwatch.comInstem 2022 Pretax Rose; Gets ToxHub RightsMay 13, 2023 | marketwatch.comComputational Toxicology Software Market Likely to Enjoy Remarkable Growth with Instem (Leadscope Inc), Lhasa Limited, MultiCASE, InotivMay 12, 2023 | lse.co.ukInstem renews long-term contract with US National Toxicology ProgramSee More Headlines Receive INS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instem and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Health Information Services Sub-IndustryN/A SectorMedical Current SymbolLON:INS CUSIPN/A CIKN/A Webwww.instem.com Phone+44-1785-825600FaxN/AEmployees500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.14 Trailing P/E Ratio5,893.57 Forward P/E Ratio17.83 P/E Growth1.89Net Income£3.34 million Net Margins5.50% Pretax MarginN/A Return on Equity6.35% Return on Assets4.62% Debt Debt-to-Equity Ratio3.47 Current Ratio0.95 Quick Ratio0.84 Sales & Book Value Annual Sales£61.63 million Price / Sales3.07 Cash FlowGBX 54.09 per share Price / Cash Flow15.25 Book ValueGBX 239 per share Price / Book3.45Miscellaneous Outstanding Shares22,900,000Free FloatN/AMarket Cap£188.95 million OptionableNot Optionable Beta0.40 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Phil J. Reason (Age 61)CEO & Exec. Director Comp: $300kMr. Nigel John Goldsmith (Age 61)CFO, Sec. & Exec. Director Comp: $166kMs. Marybeth ThompsonChief Operating OfficerDr. Gordon Smith BaxterChief Scientific OfficerMr. Mark Poggi M.B.A.Ph.D., Exec. VP of Global SalesMs. Eve LeconteChief People & Culture OfficerMr. Mike HarwoodChief Product OfficerMr. Gregor GrantExec. VP of Preclinical SolutionsMr. John LeveilleExec. VP of Clinical Trial AccelerationMore ExecutivesKey CompetitorsKoothLON:KOORenalytixLON:RENXCranewareLON:CRWTristelLON:TSTLBioventixLON:BVXPView All CompetitorsInsidersNigel GoldsmithSold 15,000 sharesTotal: £10.50 M ($700.00/share)View All Insider Transactions INS Stock - Frequently Asked Questions How have INS shares performed in 2023? Instem's stock was trading at GBX 710 at the beginning of the year. Since then, INS stock has increased by 16.2% and is now trading at GBX 825.10. View the best growth stocks for 2023 here. What other stocks do shareholders of Instem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Instem investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), DSS (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM). What is Instem's stock symbol? Instem trades on the London Stock Exchange (LON) under the ticker symbol "INS." How do I buy shares of Instem? Shares of INS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Instem's stock price today? One share of INS stock can currently be purchased for approximately GBX 825.10. How much money does Instem make? Instem (LON:INS) has a market capitalization of £188.95 million and generates £61.63 million in revenue each year. The company earns £3.34 million in net income (profit) each year or GBX 0.14 on an earnings per share basis. How many employees does Instem have? The company employs 500 workers across the globe. How can I contact Instem? Instem's mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The official website for the company is www.instem.com. The company can be reached via phone at +44-1785-825600. This page (LON:INS) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instem plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.